Yasmin® and venous thrombosis: Update of product information
2010.03.29
Active substance: drospirenone
Data from two studies into the risk of venous thromboembolic incidents due to the use of combined oral contraceptives containing drospirenone, have been evaluated by the Pharmacovigilance Working Party of the European Medicines Agency EMA .
risk information - full text (available in German only)